B12 vs NAD+: Comparing the Indexed Record
A working comparison of B12 against NAD+ begins with the indexed literature, not with catalogue description.
Compound profiles
B12 in the indexed record
Searching B12 against the PubMed index returns 33,324 records, an extensive evidence base, alongside 1,423 registered studies on ClinicalTrials.gov.
Recent indexed work appears in Food Nutr Bull, Nutrients, Pan Afr Med J, spanning 2021–2024.
- Vitamin B12 absorption and malabsorption — Vitam Horm, 2022. PMID: 35337622
- Vitamin B12 deficiency: case report and review of literature — Pan Afr Med J, 2021. PMID: 34046142
- Vitamin B12 deficiency — Vitam Horm, 2022. PMID: 35337628
- Effects of Vitamin B12 Supplementation on Cognitive Function, Depressive Symptoms, and Fatigue: A Systematic Review, Meta-Analysis, and Meta-Regression — Nutrients, 2021. PMID: 33809274
NAD+ in the indexed record
The literature on NAD+ is an extensive body of work: 76,583 PubMed-indexed records, alongside 749 registered studies on ClinicalTrials.gov.
Recent indexed work appears in Cell Metab, EMBO Mol Med, Nat Metab, spanning 2020–2024.
- NAD(+) metabolism and its roles in cellular processes during ageing — Nat Rev Mol Cell Biol, 2021. PMID: 33353981
- NAD(+) metabolism, stemness, the immune response, and cancer — Signal Transduct Target Ther, 2021. PMID: 33384409
- NAD(+) homeostasis in health and disease — Nat Metab, 2020. PMID: 32694684
- NAD(+) homeostasis in human health and disease — EMBO Mol Med, 2021. PMID: 34041853
Classification and why it matters
B12 and NAD+ sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for B12 describes conditions validated for B12: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to NAD+ without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Side-by-side research profile
| Parameter | B12 | NAD+ |
|---|---|---|
| PubMed indexed records | 33,324 | 76,583 |
| Registered studies (ClinicalTrials.gov) | 1,423 | 749 |
| Literature depth | Extensive | Extensive |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
How the literature differs
The indexed record is not symmetrical between these two compounds. NAD+ carries 43,259 more indexed records than B12, which means published methodology, characterisation data and replication attempts are more readily located for NAD+. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (1,423 vs 749) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
What the paperwork has to show
A certificate of analysis is only meaningful when it names the lot printed on the vial. Purity by HPLC and identity by mass spectrometry answer two different questions, and a document reporting one is not evidence of the other.
Selecting between them for a study design
B12 and NAD+ are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (NAD+) generally offers more methodological precedent.
Laboratory handling
Both compounds ship as lyophilised powder. Convention is storage of the sealed vial at -20°C away from light, with reconstitution immediately before experimental use. In solution, peptides are materially less stable than in lyophilised form.
Freeze-thaw cycling degrades integrity; aliquoting after reconstitution avoids repeatedly cycling one vial.
Frequently asked questions
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Are B12 and NAD+ the same compound?
No. They are structurally distinct research compounds with separate literature records — 33,324 indexed records for B12 and 76,583 for NAD+.
Which of B12 or NAD+ has more published research?
NAD+, with 76,583 indexed PubMed records against 33,324.
Related references
- NAD+ — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.